{
    "clinical_study": {
        "@rank": "67261", 
        "arm_group": [
            {
                "arm_group_label": "SAD cohorts 1-6 Experimental Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "SAD Cohorts 1-6 Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "MAD cohorts 2-5 Experimental Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MAD cohorts 2-5 Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Japanese MAD cohort 7 Experimental arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Japanese MAD cohort 7 Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This single and multiple ascending dose study is the first evaluation of PF-0626414, a\n      Selective Androgen Receptor Modulator in humans. The goal is to assess the safety,\n      tolerability, pharmacokinetics and pharmacodynamics in healthy western and Japanese male\n      subjects ."
        }, 
        "brief_title": "Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male between the ages of 21 and 50 years, inclusive (Healthy is defined as no\n             clinically relevant abnormalities identified by a detailed medical history, full\n             physical examination, including blood pressure and pulse rate measurement, 12 lead\n             ECG and clinical laboratory tests).\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n          -  Additional inclusion criteria for subjects to be enrolled in Japanese cohort only:\n             Japanese subjects who have four Japanese grandparents born in Japan.\n\n        Exclusion Criteria:\n\n          -  Serum total testosterone level <270 or >1070 ng/dL\n\n          -  Serum Prostate Specific Antigen (PSA) level >4 ng/mL.\n\n          -  Hematocrit >48%.\n\n          -  eGFR >150 ml/min/1.73m2."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02070939", 
            "org_study_id": "B7411001"
        }, 
        "intervention": [
            {
                "arm_group_label": "SAD cohorts 1-6 Experimental Arm", 
                "description": "Subjects will receive single doses of 1,3,10,30,100,200 mg of PF-06260414 (solution) in a dose escalating format", 
                "intervention_name": "PF-06260414", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SAD Cohorts 1-6 Placebo Arm", 
                "description": "Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD cohorts 2-5 Experimental Arm", 
                "description": "Subjects will receive PF-06260414 doses (solution) twice daily for 14 days", 
                "intervention_name": "PF-06260414", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD cohorts 2-5 Placebo Arm", 
                "description": "Subjects will receive PF-06260414 matching placebo doses (solution) twice daily for 14 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Japanese MAD cohort 7 Experimental arm", 
                "description": "Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days", 
                "intervention_name": "PF-06260414", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Japanese MAD cohort 7 Placebo Arm", 
                "description": "Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "Randomized", 
            "Double Blind", 
            "Placebo-Controlled", 
            "Single and Multiple Dose Escalation", 
            "Safety Tolerability", 
            "PK", 
            "PD", 
            "PF-06460414"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7411001&StudyName=Study%20To%20Evaluate%20Safety%20And%20Tolerability%20Of%20Single%20And%20Multiple%20Ascending%20Doses%20Of%20PF-%2006260414%20In%20Healthy%20Western%20And%20Japanese%20Male%"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 1, Randomized, Double Blind (Sponsor Open), Placebo Controlled, Single-And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety,Tolerability, Pharmacokinetics And Pharmacodynamics Of PF- 06260414 In Healthy Western And Japanese Male Subjects", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Changes from baseline vital signs (blood pressure, pulse rate, oral temperature and respiration rate)", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Quantitative changes in ECG intervals", 
                "measure": "Changes from baseline in 12-lead ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Incidence and severity of treatment emergent adverse events and withdrawals due to treatment emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Incidence and magnitude of treatment emergent clinical laboratory abnormalities including hematology (including total Hb and hematocrit), chemistry, fasting glucose, urinalysis", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "24 hour creatinine clearance (baseline and day 14).", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 14"
            }, 
            {
                "measure": "Changes from baseline in total testosterone, free testosterone, estradiol, LH, FSH, SHBG.", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Changes from baseline in Prostate Specific Antigen (PSA).", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Changes from baseline in total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02070939"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Single Dose: Cmax, Tmax, AUClast, AUCinf, CL/F, Vz/F, and t\u00bd,Cmax(dn), AUCinf(dn), AUClast(dn), t\u00bd.", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Multiple Dose: Cmax, Tmax Ctrough, C,av,AUC,CL/F, Vz/F, Rac , Rac,Cmax , PTR, Cmax(dn),AUC\u03c4(dn), t\u00bd.", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Urinary Pharmacokinetics: Amount of PF 06260414 excreted unchanged (AE and AE%), renal clearance (CLr).", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "The effects of PF- 06260414 on sex hormones (total testosterone, free testosterone, estradiol, SHBG, LH and FSH) will be evaluated according to the scheduled timepoints in single ascending dose study", 
                "measure": "Single Dose: AUC(hormone or PSA), C0(hormone or PSA), Maximum PCB, Cmax(hormone or PSA), Cmin(hormone or PSA), Tmax(hormone or PSA), Tmin(hormone or PSA).", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Multiple Dose: AUC(hormone or PSA), C0(hormone or PSA), Cmax(hormone or PSA), Cmin(hormone or PSA), Tmax(hormone or PSA), Tmin(hormone or PSA).", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}